Legal & General Group Plc Takes Position in Biogen Inc. $BIIB

Legal & General Group Plc purchased a new position in Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,493,289 shares of the biotechnology company’s stock, valued at approximately $322,640,000. Legal & General Group Plc owned about 1.01% of Biogen at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BIIB. BlackRock Inc. bought a new stake in shares of Biogen in the 2nd quarter valued at approximately $3,453,878,000. Norges Bank bought a new position in Biogen during the fourth quarter valued at approximately $464,408,000. Boston Partners acquired a new stake in Biogen in the fourth quarter valued at approximately $302,815,000. Deutsche Bank AG acquired a new stake in Biogen in the second quarter valued at approximately $193,165,000. Finally, Fred Alger Management LLC grew its position in Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock worth $140,576,000 after acquiring an additional 796,735 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Weiss Ratings lowered shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. Guggenheim increased their target price on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Mizuho raised their target price on Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. UBS Group boosted their price target on Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Needham & Company LLC upped their price target on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $227.79.

Biogen Price Performance

NASDAQ BIIB opened at $220.77 on Wednesday. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.85. The company has a fifty day simple moving average of $206.42 and a 200 day simple moving average of $195.12. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The company has a market cap of $32.62 billion, a P/E ratio of 39.07, a P/E/G ratio of 6.80 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.